The discovery and development of new active ingredients for a medicine is a long and expensive process which is why a patent protects new active ingredients for a certain time. When the patent expires, other pharmaceutical companies market medicines with the same active ingredient, known as “Generics”.

A generic´s active ingredient is identical to the original in terms of quality as well as quantity. Generic companies do not have to bear the high costs involved in discovering a new medicine. Thus, they are able to offer the medicine at a lower price than the original. This way, generics contribute to cost-effective medical care for the whole population whilst maintaining high quality at the same time. Dr Reddy’s Generics meet strict standards of quality, strength and purity.

Disease knows no Socio-Economic boundaries as they infect anyone regardless of wealth or stature. Hence the demand for prescription drugs rise not just in the developing countries but in the developed nations as well. As the population ages, the need to bring more people into the healthcare system also increases. The Pharmaceutical industry is challenged to find cost-effective solutions as the means to pay for medicine is not growing in tandem with the rising demand.

By providing cost-effective alternatives to highly-priced innovator brands through our branded and unbranded Generics, we at Dr. Reddy’s strive to make medicines more accessible and affordable to people all over the world.

The top four key markets for our generics business include India, Russia, US and Germany. Apart from these four markets, Dr Reddy’s has its business presence in over 45 countries through Joint Ventures, representative offices and third party arrangements.

• In India we are amongst the top ten players.
• In Germany we are amongst the top five. Germany is the largest generics market amongst the developed nations.
• In Russia we are the largest Indian Company are the sixth largest generic player. Russia is the fastest growing market amongst the emerging countries.
• In US we are in the top five in terms of the ANDA filings with 69 ANDA pending approval of which 32 are Para IV certifications